Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-09-25
2007-09-25
Stockton, Laura L. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
10952418
ABSTRACT:
Disclosed herein are methods and compositions related to compound 1or a pharmaceutically acceptable salt, or a prodrug thereof (all of which are referred to hereafter, collectively or individually, as “compound 1”), which is an antagonist of a prostaglandin EP4receptor, or is a prostaglandin EP4antagonist.Also disclosed is a method comprising administering a prostaglandin EP4antagonist to a mammal suffering from, or at risk of developing, a disease or condition selected from the group consisting of cancer, immunological disorders, neurodegenerative disorders, ocular diseases, hepatic diseases, renal diseases, septicemia, fibromyalgia, dermatological disorders, and antipyrexia.
REFERENCES:
patent: 4808608 (1989-02-01), Guindon et al.
patent: 5491254 (1996-02-01), Sato et al.
patent: 6369082 (2002-04-01), Lacombe et al.
patent: 6369089 (2002-04-01), Burk et al.
patent: 6407250 (2002-06-01), Burk et al.
patent: 6410583 (2002-06-01), Labelle et al.
patent: 2001/0051624 (2001-12-01), Jones
patent: 2003/0055077 (2003-03-01), Jones
patent: 2003/0158246 (2003-08-01), Berthelette et al.
patent: 837 052 (1998-04-01), None
patent: WO 98/25919 (1998-06-01), None
patent: WO 99/62555 (1999-12-01), None
Golub et al., Science, vol. 286, Oct. 15, 1999, pp. 531-537.
Ney, P., et al.,PGD2and its mimetic ZK 110.841 are potent inhibitors of receptor-mediated activation of human neutrophils, Eicosanoids (1991) 4:21-28.
Wright, D.H., et al., “Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist” British Journal of Pharmacology (1998) 123, 1317-1324.
Boie, Y, et al., “Molecular cloning and characterization of the human prostanoid DP receptor”Journal of Biological Chemistry, vol. 270, No. 32, Aug. 11, 1995, pp. 18910-18916.
Breyer, M.D., et al., “Functional and molecular aspects of renal prostaglandin receptors”J. Am. Soc.Nephrol, 1996;7;8-17.
Coleman, R.A., “Prostanoid Receptors”Eicosanoids From Biotechnology to Therapeutic Applications, Plenum Press, 1996, Chp. 14, 137-154.
Darius, H., et al., Inhibition of human platelets and polymorphonuclear neutrophils by the otent and metabolically stable prostaglandin D2 analog ZK 118.182European Journal of Pharm, 258(1994) 207-213.
Giles, H., et al., The classification of prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel selective and potent competitive antagonist,Br. J. Pharmacol., (1989), 96, 291-300.
Hirai, H, et al., “Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2”,J. Exp. Med, The Rockfeller Univ. Press, vol. 192, No. 2, Jan. 15, 2001, 255-261.
Ichikawa, A.,“Molecular aspects of the structures and functions of the prostaglandin E receptors”,J of Lipid Mediators and Cell Signalling, 14 (1996) 83-87.
Matsuoka, T., et al., “Prostaglandin D2 as a Mediator of allergic asthma”,Sciencevol. 287, Mar. 17, 2000, pp. 2013-2017.
Negishi, M. et al., “Prostanoid receptors and their biological actions”Prog. Lipid Res. vol. 32, No. 4, pp. 417-434, 1993.
Pons, F., et al., “Pro-inflammatory and anti-inflammatory effects of the stable prostaglandin D2 analogue ZK.182”European Journal of Pharm, 261 (1994) 237-247.
Rangachari, P.K., et al., “Effects of a selective DP receptor agonist (BW 245C) and antagonists (BW A868C) on the canine colonic epithelium : an argument for a different DP receptor”,The Journal of Pharmacology and experimental therapeutics, vol. 275, No. 2, 611-617 (1995).
Tsuri, T., et al, “Bicyclo [2.2.1]heptane and 6,6-dimethylbicyclo[3.1.1]heptane Derivatives: orally active, potent and selective prostaglandin D2 receptor antagonists”J. Med. Chem, 1997, 40, 3504-3507.
Wright, D.H., et al., “A novel biological role for prostaglandin D2 is suggested by distribution studies of the rat DP prostanoid receptor”,European Journal of Pharmacology, 377 (1999) 101-115.
Burk Robert M.
Donde Yariv
Krauss Achim H.
Woodward David
Allergan Inc.
Johnson Brent A.
Stockton Laura L.
Voet Martin A.
LandOfFree
Prostaglandin EP4 antagonist does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prostaglandin EP4 antagonist, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prostaglandin EP4 antagonist will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3793277